[
  {
    "ts": "2026-02-13T01:14:37+00:00",
    "headline": "Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update",
    "summary": "Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its inflammation and immunology portfolio, discussing expansion plans for UPLIZNA, new phase II results for daxdilimab in discoid lupus, progress in Sjögren’s syndrome studies for dazodalib",
    "url": "https://www.marketbeat.com/instant-alerts/amgen-conference-uplizna-phase-iii-plans-daxdilimab-lupus-data-and-tezspire-expansion-update-2026-02-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "f9fd3d54-bf00-3c0e-a799-8b830c93380f",
      "content": {
        "id": "f9fd3d54-bf00-3c0e-a799-8b830c93380f",
        "contentType": "STORY",
        "title": "Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update",
        "description": "",
        "summary": "Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its inflammation and immunology portfolio, discussing expansion plans for UPLIZNA, new phase II results for daxdilimab in discoid lupus, progress in Sjögren’s syndrome studies for dazodalib",
        "pubDate": "2026-02-13T01:14:37Z",
        "displayTime": "2026-02-13T01:14:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/4909f551de818c56e42d3c9ab5f5456b",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Amgen logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/du5DeAl0vfsu8qD9DGoJyw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/4909f551de818c56e42d3c9ab5f5456b.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GeOU9jSAhtvzM5tx5QWlcw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/4909f551de818c56e42d3c9ab5f5456b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/amgen-conference-uplizna-phase-iii-plans-daxdilimab-lupus-data-and-tezspire-expansion-update-2026-02-12/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-conference-uplizna-phase-iii-011437083.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]